Vedolizumab 108mg solution for subcutaneous injection in pre-filled syringe or pre-filled pen (Entyvio®) is accepted for restricted use within NHSScotland for treatment of Crohn’s disease

Approved for restricted use in adults with moderately or severely active Crohn's disease, who have had an inadequate response with, lost response to, or were intolerant of a TNFα antagonist.

Source:

Scottish Medicines Consortium